Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sathibalan Ponniah

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Women'S Health (London, England)|October 7, 2009
HER2/neu vaccines in breast cancerSteven Khoo, Sathibalan Ponniah, George E Peoples
Cancer Immunology, Immunotherapy : CII|June 10, 2008
The E75 HER2/neu peptide vaccineElizabeth A Mittendorf, Jarrod P Holmes, Sathibalan Ponniah, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 17, 2009
Therapeutic breast cancer vaccines: a new strategy for early-stage diseaseNathan M Shumway, Nuhad Ibrahim, Sathibalan Ponniah, et al.
Annals of Surgical Oncology|July 26, 2006
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancerElizabeth A Mittendorf, Catherine E Storrer, Craig D Shriver, et al.
Breast Cancer Research and Treatment|June 28, 2005
Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptidesElizabeth A Mittendorf, Catherine E Storrer, Craig D Shriver, et al.
Cancer Immunology, Immunotherapy : CII|April 19, 2007
Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patientsCarlyle Hamsher, Anna M Smith, Zia A Dehqanzada, et al.
Military Medicine|May 3, 2013
Cancer Vaccine Development Program collaborationsTravis Clifton, Jennifer A Pappas, Maureen Pavlik, et al.
Annals of Surgical Oncology|October 2, 2007
Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot studyAlexander Stojadinovic, Elizabeth A Mittendorf, Jarrod P Holmes, et al.
Surgery|March 21, 2006
Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancerElizabeth A Mittendorf, Jennifer M Gurney, Catherine E Storrer, et al.
Immunotherapy|June 5, 2014
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical responseErika J Schneble, John S Berry, Francois A Trappey, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Women'S Health (London, England)|October 7, 2009
HER2/neu vaccines in breast cancerSteven Khoo, Sathibalan Ponniah, George E Peoples
Cancer Immunology, Immunotherapy : CII|June 10, 2008
The E75 HER2/neu peptide vaccineElizabeth A Mittendorf, Jarrod P Holmes, Sathibalan Ponniah, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 17, 2009
Therapeutic breast cancer vaccines: a new strategy for early-stage diseaseNathan M Shumway, Nuhad Ibrahim, Sathibalan Ponniah, et al.
Annals of Surgical Oncology|July 26, 2006
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancerElizabeth A Mittendorf, Catherine E Storrer, Craig D Shriver, et al.
Breast Cancer Research and Treatment|June 28, 2005
Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptidesElizabeth A Mittendorf, Catherine E Storrer, Craig D Shriver, et al.
Cancer Immunology, Immunotherapy : CII|April 19, 2007
Pattern of serum immunoreactivity against breast cancer cell lysates may predict severity of disease in breast cancer patientsCarlyle Hamsher, Anna M Smith, Zia A Dehqanzada, et al.
Military Medicine|May 3, 2013
Cancer Vaccine Development Program collaborationsTravis Clifton, Jennifer A Pappas, Maureen Pavlik, et al.
Annals of Surgical Oncology|October 2, 2007
Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot studyAlexander Stojadinovic, Elizabeth A Mittendorf, Jarrod P Holmes, et al.
Surgery|March 21, 2006
Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancerElizabeth A Mittendorf, Jennifer M Gurney, Catherine E Storrer, et al.
Immunotherapy|June 5, 2014
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical responseErika J Schneble, John S Berry, Francois A Trappey, et al.
Pageof 5